-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29

Benzinga·08/25/2026 10:29:09
Listen to the news
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.